Table 3.
Proteomic analysis of B. afzelii-infected skin.
| Treatment | fla/104 gapdh | fla/100 ng | Number of total identified proteins | Total number of identified peptides | Number of Borrelia proteins | Number of Borrelia peptides |
|---|---|---|---|---|---|---|
| Day 0 of culture | ||||||
| Without lidocaine | 252 | 836 | 4,274 | 31,100 | 70 | 206 |
| With lidocaine | 271 | 838 | 4,685 | 37,300 | 64 | 186 |
| Day 7 of culture | ||||||
| Without lidocaine | N.d | 15,200 | 3,140 | 21,733 | 474 | 2,736 |
| With lidocaine | N.d | 22,700 | 3,691 | 25,427 | 397 | 1992 |
At the peak of Borrelia multiplication in the infected skin at day 7, lidocaine was injected or not (control) before the skin biopsy. Skin was collected and directly analyzed (day 0) or cultivated for 7 days and then we selected the skin with the best qPCR count to perform proteomic analysis. For each biopsy sample, mouse and Borrelia proteins were identified using nanoLC-MS/MS, once for each biopsy.